Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue

Reuters

2025/10/30

<a href="https://laohu8.com/S/OMCL">Omnicell</a> Unveils <a href="https://laohu8.com/S/MSTR">Strategy</a> to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue

Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579496117"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579496117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579496117?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579496117","market":"us","top_or_hot":-1,"title":"Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> Unveils <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-30 19:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> Unveils <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"醫療保健技術","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL5S4G8K:1","article_id":"2579496117","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579496117","pubTimestamp":1761822314,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellige","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","BK4082":"医疗保健设备","OMCL":"Omnicell"},"translate_title":"Omnicell公布推动自主药房转型和扩大经常性收入的战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":0.9},"content_text":"Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue\n    \n\n        Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}